Mineralys Therapeutics to take part in Goldman Sachs 47th Annual Global Healthcare fireside chat

Mineralys Therapeutics, Inc. said it will participate in the Goldman Sachs 47th Annual Global Healthcare Conference, a major healthcare investor event, as the company advances its aldosterone-focused drug program for hypertension and related conditions. The company announced on June 8, 2026 that its management will take part in the conference in Miami from June 8 to June 10, with a fireside chat scheduled for Tuesday, June 9 at 2:40 p.m. ET.

Mineralys Therapeutics is a biopharmaceutical company focused on diseases driven by dysregulated aldosterone. In investor materials, it describes lorundrostat as its initial product candidate, an orally administered, highly selective aldosterone synthase inhibitor, aimed at treating hypertension and comorbidities including chronic kidney disease and obstructive sleep apnea.

The conference appearance comes after Mineralys reported a key regulatory milestone for lorundrostat. In a March 12, 2026 update, the company said the U.S. Food and Drug Administration accepted its new drug application (NDA) for lorundrostat in adults with hypertension and set a Prescription Drug User Fee Act (PDUFA) target date of December 22, 2026.

Mineralys has also been financing the work needed to move lorundrostat through the FDA process. In a June 3, 2026 press release, the company said it priced an underwritten offering of 5,660,378 shares of common stock at $26.50 per share, expecting gross proceeds of about $150.0 million. The company said it intends to use net proceeds to help fund a $200.0 million upfront payment to repurchase royalty obligations under a license agreement with Tanabe Pharma Corporation.

As biotech companies approach major regulatory decision points, investor conferences often serve as a forum to reinforce development narratives, address timelines, and provide management perspective on what investors should watch next. The fireside chat format, rather than a formal slide presentation alone, typically allows follow-up discussion that can shape near-term expectations for market participants as they await later-stage trial outcomes and regulatory updates.

The June 8 announcement did not provide additional lorundrostat trial data, changes to the NDA timeline, or new guidance beyond confirming the company’s planned participation, the date, the time, and the fireside chat format. It also did not specify which individual(s) from management would participate in the session in the text of the announcement.

What to watch next is whether the June 9 webcast and any subsequent follow-up communications offer further detail on the FDA review process, the state of lorundrostat commercialization planning, or how Mineralys is thinking about remaining scientific or operational milestones. With a December 22, 2026 PDUFA target date already in place, the company’s conference commentary may be closely scrutinized for any indicates about progress and risks ahead of that decision.